Bldaxn Liquid Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts, corns, and calluses. It is intended for use in patients seeking a topical treatment option for these specific dermatological conditions.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. Following cleansing, the wart should be soaked in warm water for a duration of 5 minutes. After soaking, the area must be dried completely.

Using the provided applicator (brush), one drop of the product should be applied at a time to ensure sufficient coverage of each wart. It is essential to allow the product to fully absorb and dry after application.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any infected or reddened area is prohibited due to the potential for exacerbating the condition. Additionally, the product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, warts on the face, or warts on mucous membranes, as these conditions may lead to adverse reactions or complications.

Contact with the eyes must be avoided to prevent irritation or injury. If discomfort persists, discontinue use and consult a healthcare professional.

Warnings and Precautions

The product is intended for external use only. Healthcare professionals should advise patients to avoid contact with the eyes. In the event of accidental exposure to the eyes, it is imperative to flush the eyes with water for a minimum of 15 minutes. If the product is ingested, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients should be cautioned against using the product on irritated skin or any areas that are infected or reddened. It is also contraindicated for use on moles, birthmarks, warts with hair growth, genital warts, warts located on the face, or warts on mucous membranes.

Should discomfort persist after application, patients are advised to discontinue use and consult a healthcare professional. Additionally, it is recommended that individuals with diabetes or poor blood circulation seek medical advice prior to using this product to ensure safe application and monitoring of any potential adverse effects.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Bldaxn Liquid Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric use has not been established, and the safety and effectiveness of this medication in children have not been determined. It is essential for healthcare professionals to consult a doctor before administering this medication to pediatric patients.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established. Use is not recommended during pregnancy due to potential risks to the fetus. Healthcare professionals should consider alternative treatments for pregnant patients and weigh the benefits against the potential risks when making treatment decisions. Women of childbearing potential should be advised of these risks and the importance of effective contraception during treatment.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any unusual symptoms or adverse effects that may arise. In the event of suspected overdosage, it is recommended to initiate supportive care and symptomatic treatment as necessary.

Healthcare providers should consider contacting a poison control center or a medical toxicologist for guidance on management strategies tailored to the specific situation. Continuous assessment of the patient's clinical status is essential to ensure appropriate interventions are implemented promptly.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients on the importance of avoiding contact with the eyes while using this product. In the event that the product does come into contact with the eyes, patients should be instructed to flush their eyes with water for at least 15 minutes and seek medical attention if irritation persists.

Patients should also be made aware of the potential risks associated with swallowing the product. They should be encouraged to seek medical help or contact a Poison Control Center immediately if ingestion occurs.

It is essential for healthcare providers to recommend that patients consult with a doctor prior to using the product if they have a history of diabetes or poor blood circulation, as these conditions may affect the safety and efficacy of the product.

Finally, patients should be informed to discontinue use and consult a healthcare professional if they experience any discomfort that persists after application.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Clinicians should counsel patients to avoid contact with the eyes and to consult a doctor prior to use if they have diabetes or poor blood circulation. Patients are advised to discontinue use and seek medical advice if discomfort persists. In the event of accidental eye contact, the affected area should be flushed with water for 15 minutes, and if ingested, immediate medical assistance or contact with a Poison Control Center is necessary.

Drug Information (PDF)

This file contains official product information for Bldaxn Liquid Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)